Tiller RE. The chest roentgenogram in cystic fibrosis: a new scoring system. Pediatrics 1979;63:24-9. 3 Pierce RJ, Brown DJ, Holmes M, Cumming G, Denison DM. The estimation oflung volume from chest radiographs using shape information. Thorax 1979;34:726-34. 4 Pierce RJ, Brown DJ, Denison DM. Radiographic, scintigraphic and gas-dilution estimates of individual lung and lobar volume. Thorax 1980;35:773-80 Phenylephrine reduces blood flow in the tracheobronchial mucosa and adrenaline increases vascular resistance in the nasal mucosa4 in the dog. We therefore determined whether oaadrenoreceptor stimulation would potentiate the effects of inhaled lignocaine. The aim was to examine the antitussive effect and the oropharyngeal numbness of inhaled lignocaine and adrenaline on capsaicin-induced cough in healthy human subjects. In addition, plasma levels oflignocaine were measured to determine the degree of systemic absorption.
Lignocaine inhibits experimental cough in humans in a dose-dependent manner' and inhalation of a large dose of lignocaine has been reported to be an effective treatment in patients with severe persistent cough.23 Unfortunately, lignocaine has a short duration of action. Phenylephrine reduces blood flow in the tracheobronchial mucosa and adrenaline increases vascular resistance in the nasal mucosa4 in the dog. We therefore determined whether oaadrenoreceptor stimulation would potentiate the effects of inhaled lignocaine. The aim was to examine the antitussive effect and the oropharyngeal numbness of inhaled lignocaine and adrenaline on capsaicin-induced cough in healthy human subjects. In addition, plasma levels oflignocaine were measured to determine the degree of systemic absorption.
Methods
Ten non-smokinghealthy subjects (five women) of mean age 27 (range 18-33 years) took part in the study. They gave their written informed consent and the study was approved by the University Hospital medical ethics committee, Lund. Capsaicin (Sigma) was dissolved in ethanol and diluted with 0 9% NaCl to 0 4 gmol/l, 2 jmol/l, 10 jmol/l, and 50 gmol/l.
Capsaicin was inhaled by tidal breathing from a nebuliser (BIRD Asmastick, output 0-5 ml/min and mass median diameter 3 ,um) filled with 2 ml of solution.' A microphone and tape recorder were used to register the sounds ofbreathing and cough. The number of coughs was counted from the tape recordings. Blood samples were drawn from an arm vein into heparinised tubes. All blood samples were centrifuged and plasma was then separated and stored at -25°C until analysed by gas chromatography (Astra Alab, Sodertalje, Sweden).
The antitussive effects of nebulised lignocaine (20 mg), adrenaline (400 jg), lignocaine in combination with adrenaline (20 mg + 400 jg), and vehicle (saline) were studied on four separate study days. Treat The maximum plasma concentration after inhalation of 20 mg of lignocaine was less than 20 ng/ml, which is about 1/50 of that attained after inhalation of 400 mg with an ultrasonic nebuliser before bronchoscopy. 6 that the antitussive effect is due to anaesthesia ofthe sensory nerves locally in the airway rather than to inhibition of impulse conduction in large conducting nerves or to suppression of a putative "cough centre" in the central nervous system. Further support for this view comes from a study which showed that a high plasma concentration (>3000 ng/ml) was necessary to inhibit the cough reflex after intravenous administration.'
The present study has shown that capsaicininduced cough can be reduced by inhaled lignocaine through an action locally in the tracheobronchial tree. Inhibition of the cough reflex was significantly more pronounced than the subjective sensation of oropharyngeal anaesthesia, suggesting the involvement of separate sensory mechanisms. Adrenaline had no antitussive effect and did not alter the response to inhaled lignocaine, indicating that the combined use of these two agents on the respiratory mucosa offers no advantage over lignocaine alone.
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